ELDN

Eledon Pharmaceuticals, Inc. NASDAQ Listed Sep 17, 2014

Healthcare ·Biotechnology ·US · eledon.com

$3.86

Mkt Cap $231.4M

52w Low $1.35 77.2% of range 52w High $4.60

50d MA $3.13 200d MA $2.61

P/E (TTM) -6.6x

EV/EBITDA -1.2x

P/B 2.2x

Debt/Equity 0.0x

ROE -56.3%

P/FCF -2.0x

RSI (14) —

ATR (14) —

Beta 0.84

50d MA $3.13

200d MA $2.61

Avg Volume 1.3M

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

SIC Code

2834

CIK (SEC)

1404281

Phone

949 238 8090

19900 MacArthur Boulevard · Irvine, CA 92612 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 19, 2026	AMC	-0.20	-0.10	+50.0%	2.85	+0.7%	+1.1%	+7.6%	-6.8%	+1.0%	+1.4%	—
Nov 14, 2025	AMC	-0.22	-0.21	+4.5%	1.76	+2.3%	-8.0%	-4.9%	+0.6%	-10.3%	+3.6%	—
Aug 14, 2025	AMC	-0.23	-0.13	+43.5%	2.60	+1.2%	+1.2%	-1.1%	+0.8%	-1.5%	-0.8%	—
May 14, 2025	AMC	-0.28	-0.08	+71.4%	2.83	+0.4%	+2.1%	-0.7%	+5.9%	+0.7%	+2.9%	—
Mar 20, 2025	AMC	-0.32	-0.64	-100.0%	3.44	-2.0%	+2.0%	+2.8%	-3.9%	-2.9%	+1.2%	—
Nov 12, 2024	AMC	-0.30	-0.32	-6.7%	4.82	-2.3%	-11.4%	-3.3%	-3.1%	-2.5%	-0.5%	—
Aug 19, 2024	AMC	-0.31	-0.32	-3.2%	2.76	+2.2%	+3.3%	+0.7%	+2.8%	-1.7%	+0.0%	—
May 9, 2024	AMC	-0.37	-0.34	+8.1%	2.40	+1.2%	-3.8%	-5.2%	+6.8%	+7.3%	+11.6%	—
Mar 28, 2024	AMC	-0.38	-0.29	+23.7%	2.06	+1.9%	-3.4%	-3.0%	-12.4%	+4.1%	-2.3%	—
Nov 9, 2023	AMC	-0.41	-0.35	+14.6%	1.15	+1.7%	+0.9%	+3.4%	+4.2%	+0.0%	+0.0%	—
Aug 10, 2023	AMC	-0.47	-0.40	+14.9%	1.23	+0.0%	+0.0%	-1.6%	+2.5%	-4.8%	+9.3%	—
May 11, 2023	AMC	-0.71	-0.75	-5.6%	2.77	-4.3%	-13.0%	-3.7%	-4.7%	+1.8%	-0.4%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Nov 18	Guggenheim	Maintains	Buy → Buy	—	$1.62	$1.61	-0.6%	-4.9%	+0.6%	-10.3%	+3.6%	+11.8%
Sep 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.59	$2.59	+0.0%	-1.5%	+1.6%	+0.8%	+3.8%	-4.8%
Nov 20	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.88	$3.90	+0.5%	-0.8%	+5.7%	-1.5%	+0.0%	+6.0%
Jun 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.80	$2.81	+0.4%	+2.5%	-1.0%	-4.2%	+2.2%	+3.2%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.40	$2.43	+1.2%	-3.8%	-5.2%	+6.8%	+7.3%	+11.6%
May 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.44	$2.15	-11.9%	-7.4%	+8.0%	-1.6%	-3.8%	-5.2%
Mar 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.88	$2.07	+10.1%	+6.9%	+3.0%	+2.4%	+0.5%	-3.3%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.16	$1.16	+0.0%	+3.4%	+4.2%	+0.0%	+0.0%	+1.6%
Oct 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.33	$1.42	+6.8%	+0.8%	+6.7%	+4.2%	+7.0%	-0.9%
Aug 22	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.32	$1.39	+5.3%	+11.4%	-0.7%	+13.7%	-3.0%	-3.7%
May 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.89	$1.89	+0.0%	-2.1%	-5.4%	+20.0%	-6.2%	-2.0%
Jun 1	SVB Leerink	Maintains	Outperform → Outperform	—	$3.19	$3.19	+0.0%	+1.3%	+4.0%	-2.7%	-6.4%	+5.2%
Nov 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$5.09	$5.03	-1.2%	+2.0%	-0.2%	-2.5%	-3.2%	-3.3%
Apr 27	SVB Leerink	Maintains	Outperform → Outperform	—	$11.48	$10.90	-5.1%	-7.4%	-3.2%	-3.2%	+0.4%	-0.9%
Mar 23	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$13.65	$14.45	+5.9%	-3.2%	-7.9%	-4.0%	-9.7%	-2.4%
Feb 8	SVB Leerink	Maintains	Outperform → Outperform	—	$14.99	$16.99	+13.3%	+15.5%	+10.7%	+0.1%	-1.2%	-2.5%

Data updated apr 25, 2026 6:50am · Source: massive.com